(Q35935027)

11 August 2017

title

The role of anti-IL-2 receptor in high-risk kidney transplant patients (English)

1 reference

11 August 2017

S Jirasiritham

1

1 reference

11 August 2017

V Sumethkul

2

1 reference

11 August 2017

V Mavichak

3

1 reference

11 August 2017

P Lertsithichai

4

1 reference

11 August 2017

S Jirasiritham

5

1 reference

11 August 2017

language of work or name

English

0 references

publication date

1 September 2004

1 reference

Transplantation Proceedings

11 August 2017

published in

1 reference

11 August 2017

volume

36

1 reference

11 August 2017

issue

7

1 reference

11 August 2017

page(s)

2110-2112

1 reference

The impact of an acute rejection episode on long-term renal allograft survival (t1/2)

11 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.08.088

Cyclosporine microemulsion increases drug exposure and reduces acute rejection without incremental toxicity in de novo renal transplantation. International Sandimmun Neoral Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.08.088

A BLINDED, LONG-TERM, RANDOMIZED MULTICENTER STUDY OF MYCOPHENOLATE MOFETIL IN CADAVERIC RENAL TRANSPLANTATION

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.08.088

Relevant targets for therapy with monoclonal antibodies in allograft transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.08.088

Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.08.088

Reduction of acute renal allograft rejection by daclizumab. Daclizumab Double Therapy Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.08.088

Improved graft survival after renal transplantation in the United States, 1988 to 1996

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.08.088

Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. United States Simulect Renal Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.08.088

The impact of acute rejection episodes on long-term graft function and outcome in 1347 primary renal transplants treated by 3 cyclosporine regimens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2004.08.088

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.TRANSPROCEED.2004.08.088

1 reference

11 August 2017

1 reference